{"id":14267,"date":"2020-12-29T20:45:27","date_gmt":"2020-12-29T17:45:27","guid":{"rendered":"http:\/\/www.saranghanguk.ro\/?p=14267"},"modified":"2020-12-29T22:42:45","modified_gmt":"2020-12-29T19:42:45","slug":"compania-coreeana-celltrion-este-pregatita-sa-lanseze-tratamentul-pentru-covid-19-curand","status":"publish","type":"post","link":"https:\/\/www.saranghanguk.ro\/index.php\/2020\/12\/29\/compania-coreeana-celltrion-este-pregatita-sa-lanseze-tratamentul-pentru-covid-19-curand\/","title":{"rendered":"Compania coreean\u0103 Celltrion este preg\u0103tit\u0103 s\u0103 lanseze TRATAMENTUL pentru COVID-19 cur\u00e2nd"},"content":{"rendered":"\n<p id=\"tw-target-text\">Se a\u0219teapt\u0103 ca cei de la compania Celltrion s\u0103-\u0219i lanseze tratamentul  pentru COVID-19 chiar  luna viitoare, cresc\u00e2nd speran\u021bele c\u0103 \u00een acest fel se va putea combate noua tulpin\u0103 de coronavirus care provoac\u0103 fric\u0103 datorit\u0103 transmisibilit\u0103\u021bii sale ridicate. <\/p>\n\n\n\n<p id=\"tw-target-text\">Compania a declarat c\u0103 a solicitat aprobarea condi\u021bionat\u0103 pentru tratamentul s\u0103u, CT-P59 la Ministerul Siguran\u021bei Alimentelor \u0219i Medicamentelor. Aprobarea condi\u021bionat\u0103 este dat\u0103 unui nou medicament care a terminat studiile clinice de faz\u0103 2, dac\u0103 nu exist\u0103 alt tratament pentru boal\u0103. Dezvoltatorul de medicamente trebuie s\u0103 continue \u0219i s\u0103 finalizeze studiile clinice complete \u00een acela\u0219i timp, potrivit unui comunicat Korea Times. <\/p>\n\n\n\n<p id=\"tw-target-text\">CT-P59 reprezint\u0103 un tratament anticorp monoclonal anti-COVID-19 ce a fost realizat \u00een colaborare cu  Ministerul Siguran\u021bei Alimentelor \u0219i Medicamentelor. <\/p>\n\n\n\n<p id=\"tw-target-text\">Potrivit testelor realizate p\u00e2n\u0103 acum, CT-P59 a scurtat timpul de recuperare al pacien\u021bilor f\u0103r\u0103 efecte secundare raportate. Compania a mai spus c\u0103 medicamentul ucide coronavirusul \u00een 4-5 zile, protej\u00e2nd \u00een mod eficient pacien\u021bii cu simptome u\u0219oare de a se dezvolta \u00eentr-un caz sever.<\/p>\n\n\n\n<p id=\"tw-target-text\">La c\u00e2teva ore dup\u0103 primirea cererii de la  Celltrion, ministerul a declarat c\u0103 \u0219i-a \u00eenceput revizuirea.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" width=\"740\" height=\"493\" src=\"http:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3.jpg\" alt=\"\" class=\"wp-image-14273\" srcset=\"https:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3.jpg 740w, https:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3-300x200.jpg 300w, https:\/\/www.saranghanguk.ro\/wp-content\/uploads\/2020\/12\/optimize-3-90x60.jpg 90w\" sizes=\"(max-width: 740px) 100vw, 740px\" \/><\/figure>\n\n\n\n<p id=\"tw-target-text\">La \u00eenceputul acestei s\u0103pt\u0103m\u00e2ni, ministerul a declarat c\u0103 va scurta perioada de revizuire a medicamentelor pentru tratarea COVID-19 de la 180 de zile la 40 de zile. Av\u00e2nd \u00een vedere acest lucru, se anticipeaz\u0103 c\u0103 tratamentul va deveni disponibil la sf\u00e2r\u0219itul lunii ianuarie.<\/p>\n\n\n\n<p id=\"tw-target-text\">Studiile de faz\u0103 2 au fost efectuate pe 327 de pacien\u021bi din Coreea, Rom\u00e2nia, Spania \u0219i SUA, iar injec\u021biile finale din cadrul  tratamentului au avut loc pe 25 noiembrie.  Reprezentan\u021bii Celltrion au declarat c\u0103 au decis s\u0103 solicite aprobarea intern\u0103 imediat dup\u0103 studii, deoarece &#8220;compania crede c\u0103 a ob\u021binut suficiente dovezi \u0219i date pentru a depune spre aprobare.&#8221;<\/p>\n\n\n\n<p id=\"tw-target-text\">Deoarece studiile au fost concepute \u00een coordonare cu ministerul, Administra\u021bia SUA pentru Alimente \u0219i Medicamente (FDA) \u0219i Agen\u021bia European\u0103 pentru Medicamente, compania se a\u0219teapt\u0103 ca procedurile  de aprobare de urgen\u021b\u0103 s\u0103 se desf\u0103\u0219oare f\u0103r\u0103 probleme \u00een aceste regiuni. Compania inten\u021bioneaz\u0103 s\u0103 solicite autoriza\u021bia de utilizare de urgen\u021b\u0103 \u00een SUA \u0219i Europa, luna viitoare \u0219i va lansa \u00een cur\u00e2nd studii clinice de faz\u0103 3 \u00een 10 \u021b\u0103ri.<\/p>\n\n\n\n<p id=\"tw-target-text\">Dac\u0103 tratamentul Celltrion ob\u021bine aprobarea intern\u0103, va fi a treia companie din lume care va dezvolta de la zero un tratament COVID-19, dup\u0103 Eli Lilly \u0219i Regeneron.<\/p>\n\n\n\n<p id=\"tw-target-text\">\u00centr-o conferin\u021b\u0103 de pres\u0103 \u021binut\u0103 ieri, vicepre\u0219edintele Celltrion, Kee Woo-sung, a declarat c\u0103 CT-P59 este conceput pentru tratamentul precoce al cazurilor u\u0219oare de COVID-19, iar compania a confirmat c\u0103 medicamentul este eficient \u00eempotriva tuturor variantelor coronavirusului.<\/p>\n\n\n\n<p id=\"tw-target-text\">\u00cen aceste zile, teama asupra apari\u021biei noii tulpini COVID-19  a crescut \u00een Coreea. Administra\u021bia Central\u0103 pentru Controlul Bolilor a confirmat c\u0103 o noua tulpin\u0103 de coronavirus care se r\u0103sp\u00e2nde\u0219te \u00een Marea Britanie a infectat trei coreeni care au intrat \u00een Coreea, pe  data de 23 decembrie.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Se a\u0219teapt\u0103 ca cei de la compania Celltrion s\u0103-\u0219i lanseze tratamentul pentru COVID-19 chiar luna viitoare, cresc\u00e2nd speran\u021bele c\u0103 \u00een..<\/p>\n","protected":false},"author":8,"featured_media":14273,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[17],"tags":[3439,3441,2813,2833,3440,3442,3438],"_links":{"self":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts\/14267"}],"collection":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/comments?post=14267"}],"version-history":[{"count":22,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts\/14267\/revisions"}],"predecessor-version":[{"id":14329,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/posts\/14267\/revisions\/14329"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/media\/14273"}],"wp:attachment":[{"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/media?parent=14267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/categories?post=14267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.saranghanguk.ro\/index.php\/wp-json\/wp\/v2\/tags?post=14267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}